NLS Biotech News

Agreement – August 26, 2025

BioArctic and Novartis sign agreement – an upfront payment of USD 30 million

The company has entered into an option, collaboration and license agreement with Novartis Pharma regarding a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed target in neurodegeneration.

Biotech Business – September 22, 2025

Alvotech receives 3 marketing approvals in Japan

Alvotech has announced that its commercialization partner in Japan, Fuji Pharma, has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare.

Biotech article – September 15, 2025

In-Depth Review: Modern Biotech in Finland

Biotechnology employs 19,400 in Finland – modern biotech is growing, but regulation and commercialization slow it down.

Biotech Business – September 8, 2025

Alligator Bioscience in evaluation and option agreement

The agreement has been made with an infectious disease company regarding the company’s proprietary RUBY bispecific antibody format.

Biotech Business – September 2, 2025

AdjuTec Pharma to lead EUR 2.2 million Eurostars Project

The program will investigate new antibiotics for the treatment of patients with severe lung infections caused by multidrug-resistant bacteria.

Clinical trials

Clinical Trials – September 24, 2025

New study aims to provide more cancer patients with targeted treatments

The new, national study uses genetic analysis of tumors to match cancer patients with targeted drugs – even when these are not yet approved for their specific diagnosis.

Clinical Trials – September 17, 2025

AnaCardio completes target enrollment in Phase 2a study

AnaCardio has announced that its ongoing Phase 2a study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) is fully enrolled and remains on track to report results by year-end 2025.

Clinical Trials – September 15, 2025

Cinclus Pharma screens first patient in Phase III trial

The first patient has been screened in the company’s HEEALING 1 Phase III trial evaluating linaprazan glurate for the treatment of erosive gastroesophageal reflux disease (GERD).

Clinical Trials – September 8, 2025

Orexo announces positive in vivo data

The company has announced pharmacokinetic in-vivo data for a powder-based intranasal semaglutide formulation developed with the AmorphOX technology.

Clinical Trials – September 1, 2025

SweTrial is a reality

The government decided in the end of July 2025 to establish the SweTrial partnership, an initiative aimed to strengthen Sweden’s role as a life science nation and make it easier to conduct clinical trials in the country.

Clinical Trials – August 27, 2025

Active lymphoma eliminated in 4 out of 6 patients in Elicera’s CARMA study

Elicera Therapeutics has announced preliminary data from the first two cohorts of the ongoing Phase I/IIa CARMA study with ELC-301.

Clinical Trials – August 4, 2025

Hansa Biopharma announces new supportive trial data

The company has announced topline results from three patients with Duchenne muscular dystrophy (DMD) treated with Hansa’s imlifidase prior to receiving Sarepta’s ELEVIDYS in the SRP-9001-104 trial.

Clinical Trials – June 19, 2025

BioArctic to initiate next cohorts in Phase 2a study

The interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated.

Clinical Trials – June 18, 2025

Kancera reports positive top-line results

The company has announced results from the KANDOVA study, a one-arm, open-label, multi-centre combined phase Ib/IIa study of KAND567 in combination with carboplatin in ovarian cancer.

Clinical Trials – June 18, 2025

Abera announces new study results

The company has presented results from a recently completed study that further demonstrates the potential of its vaccine platform for pandemic preparedness.

Profiles in Biotech

Profiles in Biotech – April 23, 2024

Mia Phillipson: Pioneering immunotherapies

Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur.

Profiles in Biotech – November 28, 2023

Kristian Tryggvason: Reshaping the cell therapy sector

The previous founder and CEO of BioLamina has gone back to business development, and with his newly founded company he aims to redefine cell therapy development even further.

Profiles in Biotech – July 28, 2021

Mathias Uhlén: Driven by curiosity and courage

Being a scientist or an entrepreneur is hard enough. Doing both at the same time sounds like an Olympic sport.

Profiles in Biotech – March 8, 2021

Sara Mangsbo – Scientist and entrepreneur

An academic and an entrepreneur, Dr. Sara Mangsbo, PhD, has found a way to integrate her skills and interests so that they complement and augment her passions.

Profiles in Biotech – January 7, 2021

Evelina Vågesjö: ”I want to see my work go beyond the lab”

What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company.

Profiles in Biotech – October 8, 2020

Robert Langer: Making a difference in medicine

Massachusetts Institute of Technology (MIT) in the US has produced more than its share of engineers and computer scientists, but unlike many of his peers, alumnus Dr. Robert Langer, ScD, turned his chemical engineering skills to medicine, becoming one of the world’s leaders in perfecting effective drug delivery systems.

Profiles in Biotech – June 13, 2018

Britt Meelby Jensen: Accelerating Danish biotech business

She has been called the Danish biotech queen and she is not afraid of responsibility in her role as CEO. On the contrary, Britt Meelby Jensen enjoys leading, setting ambitious goals and accelerating company growth.

Profiles in Biotech – October 6, 2017

Next-generation biotech entrepreneurs

For young scientists and engineers, a startup can be part of early training and education.

Profiles in Biotech – December 16, 2016

Agnete Fredriksen: “You really need to have drive to make it work”

Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula.

More biotech stories

Biotech Business - September 23, 2025

Elicera’s US patent application still under examination

The company has announced that the ongoing patent application for the iTANK platform in the United States is still under examination by the United States Patent and Trademark Office (USPTO).

Biotech Business - August 29, 2025

Modus Therapeutics raises approximately SEK 28.3 million

The net proceeds of approximately SEK 24.4 million, of which approximately SEK 5 million refers to set-off against outstanding loans from Modus’ largest shareholder Karolinska Development, and after transaction costs of approximately SEK 3.9 million, will primarily be used to finance clinical activities, including the ongoing phase II study, states the company.

Biotech Business - August 27, 2025

BioArctic to evaluate Beactica’s Eclipsor technology

Beactica Therapeutics has announced that BioArctic, as part of their ambition to broaden its pipeline, will evaluate Beactica’s Eclipsor technology platform and its potential use within CNS disorders.

Biotech Business - August 27, 2025

Nykode Therapeutics announces updated strategy

The updated strategy includes prioritization of VB10.16 as the lead clinical asset and value driver, given the company’s increasing conviction in its potential to treat HPV16 positive cancers.

Biotech Business - August 25, 2025

Leqembi launched in the EU – Austria and Germany will mark the first launches

BioArctic's partner Eisai has announced that the launch of Leqembi in the EU started in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025.